- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
Journal, HEOR: Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States. (Pubmed Central) - Nov 24, 2021
Tepper reports grants from Allergan, Amgen, ElectroCore, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano, outside the submitted work; personal fees from Dartmouth-Hitchcock Medical Center, American Headache Society, Thomas Jefferson University, Aeon, Align Strategies, Allergan/AbbVie, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, ClearView Healthcare Partners, CoolTech, CRG, Currax, Decision Resources, DeepBench, DRG, Eli Lilly, Equinox, ExpertConnect, GLG, Guidepoint Global Healthcare Consultancy Group, Health Science Communications, HMP Communications, Impel, InteractiveForums, M3 Global Research, Magellan Rx Management, Medicxi, Navigant Consulting, Neurorelief, Nordic BioTech, Novartis, Pulmatrix, Reckner Healthcare, Relevale, SAI MedPartners, Satsuma, Slingshot Insights, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, System Analytic, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, Zosano, Krog and Partners, and Lundbeck, outside the submitted work; and CME honoraria from American Academy of Neurology, American Headache Society, Cleveland Clinic Foundation, Diamond Headache Clinic, Elsevier, Forefront Collaborative, Hamilton General Hospital, Ontario, Canada, Headache Cooperative of New England, Henry Ford Hospital, Detroit, Inova, Medical Learning Institute PeerView, Medical Education Speakers Network, Miller Medical Communications, North American Center for CME, Physicians' Education Resource, Rockpointe, ScientiaCME, WebMD/Medscape. The abstract and poster of these results were presented at The Migraine Trust Virtual Symposium (MTIS), October 3-9, 2020.
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal: Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study. (Pubmed Central) - Nov 17, 2021
The abstract and poster of these results were presented at The Migraine Trust Virtual Symposium (MTIS), October 3-9, 2020. In patients with chronic migraine, the 3 CGRP monoclonal antibodies were well tolerated, and reduced the number of severe headache days.
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Journal: Erenumab in Chronic Migraine: An Australian Experience. (Pubmed Central) - Nov 17, 2021
This is the first report from 3 Australian headache centers about erenumab in the real world. Our analysis has supported erenumab as an effective and well-tolerated migraine preventative therapy for patients with chronic migraine who have failed many preventative therapies.
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal: Erenumab-Induced Severe Nausea Leading to Smoking Cessation: A Retrospective Case Series. (Pubmed Central) - Nov 17, 2021
To the best of our knowledge, this is the first report of severe nausea secondary to erenumab administration and smoking cigarettes, which finally resulted in complete cigarette smoking cessation. As such, further study is indicated on the benefit of erenumab and other calcitonin gene-related peptide antagonists in migraineurs who smoke to promote smoking cessation.
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Clinical, Retrospective data, Journal, HEOR, Real-world evidence: Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. (Pubmed Central) - Nov 10, 2021
TELESCOPE confirms positive treatment responses with erenumab shown in clinical trials in a real-world multi-centre setting. The results show consistently positive experiences of physicians utilizing erenumab in clinical practice and underline that therapy with this monoclonal antibody is effective in migraine patients, particular in those, who have failed several prophylactic therapies.
- |||||||||| Poteligeo (mogamulizumab) / Kyowa Kirin, Aimovig (erenumab) / Amgen, Novartis
Journal: Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control. (Pubmed Central) - Nov 6, 2021
GLP-1 R agonists have been widely used to increase insulin secretion to lower blood glucose levels for the treatment of type 1 and type 2 diabetes, whereas GLP-1 R antagonists have applications in the treatment of severe hypoglycemia associated with bariatric surgery and hyperinsulinomic hypoglycemia. Here we present the discovery and creation of both antagonistic and agonistic GLP-1 R antibodies by panning this GPCR-focused phage display library on a GLP-1 R-overexpressing Chinese hamster ovary cell line and demonstrate their in vitro and in vivo functional activity.
- |||||||||| Journal, Adverse events: The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. (Pubmed Central) - Nov 6, 2021
Moreover, because of their physicochemical properties, these agents are hepato-friendly and do not cross the blood-brain barrier (highlighting the relevance of peripheral mechanisms in migraine). Nevertheless, apart from potential cardiovascular side effects, the interaction with AMY receptors and immunogenicity induced by autoantibodies against mAbs could be a concern for the safety of long-term treatment with these molecules.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) - Nov 2, 2021
P2, N=30, Recruiting,
Nevertheless, apart from potential cardiovascular side effects, the interaction with AMY receptors and immunogenicity induced by autoantibodies against mAbs could be a concern for the safety of long-term treatment with these molecules. Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jun 2022 | Initiation date: May 2021 --> Nov 2021 | Trial primary completion date: Dec 2021 --> May 2022
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal, Combination therapy: Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. (Pubmed Central) - Oct 30, 2021
Thus, the results of this study suggest favorable outcomes with the addition of erenumab to patients who were still suffering while receiving onabotulinumtoxinA therapy. Additional investigation is needed to determine if erenumab in combination with onabotulinumtoxinA has an enhanced effect on the modulation of CGRP release from peripheral unmyelinated C fibers while also blocking CGRP receptors in the myelinated A-delta fibers.
- |||||||||| Nurtec ODT (rimegepant ODT) / Portage
Journal: Rimegepant: acute treatment for migraine headaches. (Pubmed Central) - Oct 30, 2021
Rimegepant is one of these newly approved agents for acute migraine treatment in adults with or without aura. Rimegepant has been found to decrease pain and symptoms associated with migraine attacks and is generally well-tolerated.
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study. (Pubmed Central) - Oct 27, 2021
P=N/A
Impaired wound healing might be relevant side effects of CGRP antibody therapy and anamnesis within the course of treatment should also include possible observation of impaired wound healing or planned surgery. Different migraine phenotypes, characterized by different treatment susceptibility, may exist as suggested by the divergent behavior between neurophysiological and biomolecular findings in 30% Responder vs. NON-responder patients.The study protocol was registered at clinicaltrials.gov (NCT04361721).
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine's Prophylaxis. (Pubmed Central) - Oct 14, 2021
The MIDAS was administered to patients to assess the disability related to migraine; at the end of treatment, a statistically significant reduction in the mean number of monthly migraine days, acute medication use per month, and MIDAS questionnaire score was observed; as a preventive treatment of episodic and chronic migraine, our analysis data confirm the efficacy of Erenumab for the prevention of the migraine. The success is achieved in 96% of cases.
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Biomarker, Clinical, Journal: CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab. (Pubmed Central) - Oct 14, 2021
Our study confirmed the safety and efficacy of CGRP inhibition in real-life, high-challenging patients. Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker.
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Journal: Refractory migraine profile in CGRP-monoclonal antibodies scenario. (Pubmed Central) - Oct 3, 2021
We outline that higher frequency of migraine attacks, medication overuse and pain catastrophizing characterize patients with Ref-M not responsive to CGRP-mAbs. In this frame, olanzapine effectiveness on frequency and pain intensity of migraine attacks supports the hypothesis that migraine refractoriness may be subtended by a prominent involvement of the dopaminergic pathway.
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Clinical: Open Access: Risk of #hypertension in #erenumab -treated patients with #migraine: Analyses of clinical trial & postmarketing data @daviddodick @StewartTepper J Ailani, N Pannacciulli, M Navetta, B Loop, F Zhang, A Khodavirdi, A Mann, A Abdrabboh, J Kalim https://t.co/v3SobOLjhj (Twitter) - Oct 1, 2021
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab) / Amgen, Novartis
Clinical, Observational data, Journal, HEOR, Real-world evidence: The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. (Pubmed Central) - Sep 30, 2021
In this frame, olanzapine effectiveness on frequency and pain intensity of migraine attacks supports the hypothesis that migraine refractoriness may be subtended by a prominent involvement of the dopaminergic pathway. In real-world clinical practice, monoclonal antibodies against CGRP proved to be effective treatments in resistant migraine patients.
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, Adverse events: Letter to the editor regarding "Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database". (Pubmed Central) - Sep 30, 2021
In real-world clinical practice, monoclonal antibodies against CGRP proved to be effective treatments in resistant migraine patients. No abstract available
- |||||||||| Supraorbital Neuromodulation For Intractable Chronic Migraines (Exhibit Hall) - Sep 25, 2021 - Abstract #ASA2021ASA_4484;
She tried numerous pharmacologic agents including galcanezumab, erenumab, nortriptyline, amitriptyline, gabapentin, aripiprazole, duloxetine, topiramax, rizatriptan, ubrogepant, sumatriptan and procedural therapy including Botox with no resolution of symptoms. Chronic pain management was consulted, and she underwent a successful bilateral supraorbital nerve stimulator trial with 80% improvement in symptoms followed by permanent placement of stimulator leads and pulse generator.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Erenumab For Treatment of Hemicrania Continua (clinicaltrials.gov) - Sep 24, 2021
P2, N=20, Recruiting,
Chronic pain management was consulted, and she underwent a successful bilateral supraorbital nerve stimulator trial with 80% improvement in symptoms followed by permanent placement of stimulator leads and pulse generator. Not yet recruiting --> Recruiting
- |||||||||| Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal: Predictors of response to erenumab after 12 months of treatment. (Pubmed Central) - Sep 24, 2021
Not yet recruiting --> Recruiting Patients with longer medication overuse-headache duration, higher analgesic intake, and a higher number of previous preventive treatment failures may receive less benefit with erenumab.
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Retrospective data, Journal, Real-world evidence: CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. (Pubmed Central) - Sep 22, 2021
Patients with longer medication overuse-headache duration, higher analgesic intake, and a higher number of previous preventive treatment failures may receive less benefit with erenumab. Despite the low responder rate, CGRP antibodies can be effective at least in a few cases of severely affected patients with drug resistant migraine and chronic daily headache.
|
